tirzepatide/Finding
One finding, on its own
A single claim from the graph, with the evidence strength computed from its study, the sentence it was drawn from, and the paper. This address does not change.
Decreases body mass
ModerateEvidence strength: moderate. Human evidence with one recorded weakness, or capped at moderate by its design or by unread numbers.Findingreplicated ×2“Pooled analysis demonstrated a reduction in body weight in patients receiving tirzepatide comparing with placebo (WMD=-10.80, 95%CI:-10.80 to -9.99, p < 0.00001), indicating a substantial effect of the treatment.”
Quoted verbatim from Efficacy and safety of tirzepatide for weight loss in patients with obesity or type 2 diabetes: a systematic review and meta-analysis.. - Study
- meta-analysis
- Dose
- 5, 10 or 15 mg once weekly
- Population
- Adults with obesity or type 2 diabetes in placebo-controlled phase 1 to 3 trials, pooled across 5, 10 and 15 mg doses
Efficacy and safety of tirzepatide for weight loss in patients with obesity or type 2 diabetes: a systematic review and meta-analysis.2025PMID:40747302Permalink
Keep reading
- Everything the graph holds on tirzepatide
- Every compound studied against Body mass
- How to read the evidence strength and the marks
To cite this finding: https://catalystproject.ai/e/01M45MMYJ5011S6VQ5ATQEXJ9J